OBJECTIVES
To present the progresses, achievements, and the challenges along with its feasible alternative solutions to guarantee the production of safe and effective antivenoms and its timely availability in the region of the Americas.
To share the technical cooperation opportunities established within the RELAPA framework.
To understand and assess the antivenom production from a quality and regulatory perspective.
To discuss the strategies to strengthen RELAPA, in order to meet the WHO objective of achieving a 50% reduction in mortality and long-term effects by snakebite envenoming by 2030.
PLACE AND DATE
Hotel Grand Mercure, Rio de Janeiro, Brazil, from 13 to the 15 May 2025.
PARTICIPANTS
RELAPA laboratories:
- National Institute of Biological Production, ANLIS “Dr. Carlos Malbrán” (Argentina)
- Biological Institute “Dr. Tomas Perón” (Argentina)
- National Institute of Health Laboratories — INLASA (Bolivia)
- Butantan Institute – IB (Brazil)
- Ezequiel Dias Foundation – FUNED (Brazil)
- Production and Research of Immunobiological Centre – CPPI (Brazil)
- Vital Brazil Institute – IVB (Brazil)
- National Institute of Health – INS (Colombia)
- Clodomiro Picado Institute – ICP (Costa Rica)
- National Institute of Public Health Research – INSPI – Dr. Leopoldo Izquieta Pérez (Ecuador)
- National Centre for Biological Products — National Institute of Health — CNPB (Peru)
- Biotechnology Centre, Faculty of Pharmacy of the Central University of Venezuela — BIOTECFAR (Venezuela)
PANAFTOSA/VPH-PAHO/WHO
Regional experts from PANAFTOSA/VPH-PAHO/WHO
PAHO/WHO Strategic Fund (SF)
Department of Innovation, Access to Medicines and Health Technologies (IMT), Special Program of the Regional Platform on Innovation and Production (PR) of PAHO/WHO
Department of Communicable Diseases and Environmental Determinants of Health (CDE) of PAHO/WHO
National Secretariat of Science, Technology, and Innovation (SENACYT), Panama